Windows 11 Update Meant to Fix Game Crashes Is Failing to Install: Reports
Microsoft's June 2025 cumulative update for Windows 11, KB5063060, is causing trouble for quite a few users. The worst part is that this update comes after the earlier KB5060842 patch that was released to fix problems with Easy Anti-Cheat. Now, users are reporting that KB5063060 is failing to install, with error codes such as 0x800f0922, 0x80070002, 0x80070306, and 0x800f0991 showing up during the process, as reported by Windows Latest.
Some users say the update gets stuck at 100% completion, but the system doesn't boot up. Quite a few users have also reported that the update causes issues beyond installation failures. Some have experienced system freezes or crashes when playing games, even after installing the patch that was supposed to fix these problems.
External monitors displaying purple-green colors over HDMI connections are also reported, but the colors disappear once the update is removed. Users have also reported problems with Bluetooth connectivity. They need to reconnect their devices after every restart and often find duplicate entries in the Control Panel.
Some have also reported slow or unstable network connections after installing the update.
For those affected, Microsoft says to uninstall KB5063060 through the Windows Update settings if problems occur. Users can also try downloading the update manually from the Microsoft Update Catalog or wait for a probable fix in a future update. Most users are not running into these problems.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
36 minutes ago
- Forbes
From Expense To Asset: How Today's AI Investments Can Save You Money
Michael Ringman is CIO at TELUS Digital (formerly TELUS International), providing digital-first, AI-fueled customer experiences. Whatever sector you're in, you've no doubt been thinking about the mounting pressures facing your business. Now more than ever, it's critical to strategically prioritize any and all investments. If you're looking for a sign to invest in generative AI (GenAI) solutions, here it is: According to a 2024 IDC–Microsoft survey of 4,000 business leaders tasked with bringing AI into their operations, for every dollar invested, you can expect to get about 3.7 times back. And that ROI is projected to climb as both GenAI and its adoption continue to grow. However, realizing this ROI takes time. According to KPMG, as reported in The CFO, "nearly 70% of leaders plan to spend between $50 million and $250 million on related [GenAI] Yet as we look to the future of GenAI, it's clear that the efficiency gains, cost savings and competitive advantages are too significant to ignore. With more successful use cases emerging and GenAI tools maturing rapidly, the question is no longer if businesses should invest in this technology, but how to do it right. Spending Money To Save Money It may feel counterintuitive to invest in new technologies when markets are facing uncertainty, but GenAI is already making tangible differences. Microsoft recently published a list of 261 success stories about how its GenAI solutions were used to save money, amplify efficiencies, drive productivity and extend the capabilities of organizations globally. Regardless of economic conditions, customers' expectations of digital experiences will never decline. If anything, those expectations will continuously rise as competitors and new market entrants set higher bars for service. Those bars are greatly influenced by companies' embrace of new and emerging technologies. Nvidia's "State of AI in Financial Services" survey notes that one of the top GenAI ROI use cases is customer experience (CX) and engagement. Notably, the report states that the use of GenAI for CX "has more than doubled, rising from 25% to 60%. This surge is driven by the increasing availability, cost efficiency and scalability of generative AI technologies for powering more sophisticated and accurate digital assistants that can enhance customer interactions." The report also says roughly two-thirds of respondents saw AI drive a 5% increase in revenue and a 5% reduction in annual costs. It also tracked an uptick in the number of companies using GenAI, and in the variety of ways the technology is used. GenAI can be deployed both as agent-facing tools to empower employees and as customer-facing solutions, including autonomous AI agents, to handle interactions independently. But these applications aren't the only ways AI drives value. Meaningfully supporting your company's ability to serve and engage customers takes a more profound and big-picture implementation across the employee experience, business operations, hiring processes and supply chain management. Only when your company is working in harmony across all departments can you fully realize the ROI potential of your AI investments. Bringing GenAI Assistants Into The Fold GenAI has changed the way companies handle communications, information, performance data and innovation. Employees are increasingly turning to GenAI tools to enhance their productivity, streamline workflows and tackle complex problems more efficiently. This is happening whether or not your company has adopted and implemented GenAI. Recently, my firm, TELUS Digital, revealed that a majority of employees depend on GenAI assistants in their day-to-day work and will use publicly available large language models (LLMs) like ChatGPT if none are available internally. What's more, 57% of respondents admitted to entering sensitive information, including customer names and contact details, into publicly available GenAI assistants, making the need for a secure, enterprise-safe GenAI platform even more evident. Unsurprisingly, employees reported that GenAI assistants helped them work faster, improved their performance and reduced strain caused by repetitive tasks, but the availability of GenAI assistants also has impacts on talent acquisition and recruitment. In fact, our survey found that 44% of employees would be more likely to quit if their company didn't allow AI assistants, and 59% said they'd prioritize applying for jobs at companies that allow AI assistant usage. GenAI is becoming an increasingly crucial part of employees' day-to-day lives, and businesses can no longer simply ban the use of AI at work. Given the workforce demand for GenAI assistants, it's incumbent upon companies to embrace GenAI and work to fill skill gaps now. The Cost Of Inaction Regardless of data to the contrary, many business leaders believe GenAI may still be too risky to invest in. Choosing to delay adoption is not the safe bet some may think it is. Late adopters may experience escalating implementation costs, widening skill gaps and dissatisfaction among customers who are benefiting from AI-enabled services elsewhere. The reality is, the capabilities of safe and responsible GenAI are expanding by leaps and bounds every day. McKinsey recently noted that transparency and explainability of some of the leading LLMs doubled or tripled between 2023 and 2024, based on Stanford University's Transparency Index. GenAI is continually becoming better at accuracy, reasoning and even independent decision-making. For those considering GenAI investments, best practices dictate a few clear steppingstones: • Conduct an AI readiness assessment. • Start small with pilot projects with a fast time to value. • Develop a phased implementation strategy. • Establish clear benchmarks and KPIs for tracking ROI and other metrics. • Develop comprehensive training programs and risk and governance frameworks that include human oversight. • Work with an experienced partner to benefit from their expertise, technology and economies of scale. Taking The Leap To drive efficiencies and reduce costs on a sustainable basis means investing strategically in AI today. As our executive vice chair of the board, Jeff Puritt, previously shared, "Whether your organization is poised to thrive, highly constrained, or in a fight to survive, investments in your people, technology, and communities are measurably beneficial to the bottom line. ... Doing the right thing is the right way to inoculate your business against exogenous events, while positioning your brand for sustainable growth in even the most trying of times." Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
WIRED
39 minutes ago
- WIRED
Microsoft Says Its New AI System Diagnosed Patients 4 Times More Accurately Than Human Doctors
Jun 30, 2025 9:00 AM The tech giant poached several top Google researchers to help build a powerful AI tool that can diagnose patients and potentially cut health care costs. Microsoft built an AI system called the MAI Diagnostic Orchestrator that the company says can diagnose ailments. Photograph:Microsoft has taken 'a genuine step towards medical superintelligence,' says Mustafa Suleyman, CEO of the company's artificial intelligence arm. The tech giant says its powerful new AI tool can diagnose disease four times more accurately and at significantly less cost than a panel of human physicians. The experiment tested whether the tool could correctly diagnose a patient with an ailment, mimicking work typically done by a human doctor. The Microsoft team used 304 case studies sourced from the New England Journal of Medicine to devise a test called the Sequential Diagnosis Benchmark (SDBench). A language model broke down each case into a step-by-step process that a doctor would perform in order to reach a diagnosis. Microsoft's researchers then built a system called the MAI Diagnostic Orchestrator (MAI-DxO) that queries several leading AI models—including OpenAI's GPT, Google's Gemini, Anthropic's Claude, Meta's Llama, and xAI's Grok—in a way that loosely mimics several human experts working together. In their experiment, MAI-DxO outperformed human doctors, achieving an accuracy of 80 percent compared to the doctors' 20 percent. It also reduced costs by 20 percent by selecting less expensive tests and procedures. "This orchestration mechanism—multiple agents that work together in this chain-of-debate style—that's what's going to drive us closer to medical superintelligence,' Suleyman says. The company poached several Google AI researchers to help with the effort—yet another sign of an intensifying war for top AI expertise in the tech industry. Suleyman was previously an executive at Google working on AI. AI is already widely used in some parts of the US health care industry, including helping radiologists interpret scans. The latest multimodal AI models have the potential to act as more general diagnostic tools, though the use of AI in health care raises its own issues, particularly related to bias from training data that's skewed toward particular demographics. Microsoft has not yet decided if it will try to commercialize the technology, but the same executive, who spoke on the condition of anonymity, said the company could integrate it into Bing to help users diagnose ailments. The company could also develop tools to help medical experts improve or even automate patient care. 'What you'll see over the next couple of years is us doing more and more work proving these systems out in the real world,' Suleyman says. The project is the latest in a growing body of research showing how AI models can diagnose disease. In the last few years, both Microsoft and Google have published papers showing that large language models can accurately diagnose an ailment when given access to medical records. The new Microsoft research differs from previous work in that it more accurately replicates the way human physicians diagnose disease—by analyzing symptoms, ordering tests, and performing further analysis until a diagnosis is reached. Microsoft describes the way that it combined several frontier AI models as 'a path to medical superintelligence,' in a blog post about the project today. The project also suggests that AI could help lower health care costs, a critical issue, particularly in the US. "Our model performs incredibly well, both getting to the diagnosis and getting to that diagnosis very cost effectively," says Dominic King, a vice president at Microsoft who is involved with the project. 'It is quite exciting,' says David Sontag, a scientist at MIT and cofounder of Layer Health, a startup that builds medical AI tools. Sontag says the work is important not only because it more closely mirrors the way physicians operate but also because it is rigorous about addressing potential issues with the underlying methodology. 'That's what makes this paper strong,' he says. But Sontag says that Microsoft's findings should be treated with some caution because doctors in the study were asked not to use any additional tools to help with their diagnosis, which may not be a reflection of how they operate in real life. He adds that it remains to be seen whether the AI system would significantly reduce costs in practice. The doctors involved in the study may have taken into account factors that the AI could not, such as a patient's tolerance for a procedure or the availability of a particular medical instrument. 'This is an impressive report because it tackles highly complex cases for diagnosis,' says Eric Topol, a scientist at the Scripps Research Institute. Showing that AI could, in theory, reduce the cost of medical care is novel, he adds. Both Topol and Sontag of MIT say that the next step in validating the potential of Microsoft's system ahead of general deployment would be demonstrating the tool's effectiveness in a clinical trial comparing its results with those of real doctors treating real patients. 'Then you can get a very rigorous evaluation of cost,' Sontag says.
Newsweek
41 minutes ago
- Newsweek
New Microsoft AI Research Edges Towards 'Medical Superintelligence'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Microsoft AI has unveiled new research demonstrating AI's abilities in sequential diagnostics—rivaling physicians in both accurate and cost-effective recommendations. The company's announcement on Monday morning was two-fold, introducing a benchmark to prove the performance of AI diagnostics tools against human experts, and a model-agnostic orchestrator to highlight AI's capabilities when stacked against that benchmark. Mufasa Suleyman, CEO of Microsoft AI, believes this research brings us one step closer to "medical superintelligence." "The simple way to understand medical superintelligence is that it is a model which is multiple times better than the best humans in the world, that has the breadth of all or most of the expert clinicians worldwide, combined with the depth of any given expert," the AI pioneer told Newsweek in an exclusive interview ahead of the announcement. The interactive Sequential Diagnosis Benchmark, or SDBench, took 304 complex cases from the New England Journal of Medicine (NEJM) clinicopathological conference, which are historically challenging to diagnose, and translated them into step-by-step diagnostic encounters that mimic clinical decision-making processes. Each day, more than 50 million health-related searches are conducted across Microsoft's AI consumer products, including Copilot, Bing, Edge and MSN. AI's advancements in sequential diagnostics could lead to more helpful, accurate responses, Microsoft AI... Each day, more than 50 million health-related searches are conducted across Microsoft's AI consumer products, including Copilot, Bing, Edge and MSN. AI's advancements in sequential diagnostics could lead to more helpful, accurate responses, Microsoft AI executives told Newsweek. MoreSDBench presents physicians or AI models with a short case abstract. Then, the human or model must ask questions and order tests to inform their diagnosis. A "gatekeeper model" reveals information only when explicitly asked for it. The final diagnosis is compared to the NEJM's gold standard and assessed for both accuracy and cost. Microsoft's new model-agnostic MAI Diagnostic Orchestrator (MAI-DxO) achieved 85.5 percent diagnostic accuracy—outperforming generalist physicians, who reached the correct diagnosis 20 percent of the time, on average. MAI-DxO also reduced diagnostic costs by 20 percent compared to physicians by ordering fewer expensive tests and reaching their clinical decisions more quickly. Since MAI-DxO is model-agnostic, it can be generalized across models from the OpenAI, Gemini, Claude, Grok, DeepMind and Llama families, according to Microsoft. This graphic from Microsoft's research paper illustrates SDBench's assessment process. Three agents orchestrate the "conversation" between SDBench and a human or AI model. Via the Diagnostic Agent (yellow), humans or AI models may ask questions... This graphic from Microsoft's research paper illustrates SDBench's assessment process. Three agents orchestrate the "conversation" between SDBench and a human or AI model. Via the Diagnostic Agent (yellow), humans or AI models may ask questions about patient history, exam findings and test results. The Gatekeeper Agent (purple) assess those requests and determines which information to relay, if any, using a database of NEJM CPC cases. The Judge Agent (blue) decides whether the final diagnosis is aligned with NEJM's gold-standard. Throughout the process, the Diagnostic Agent tracks estimated costs of the diagnostic workup, which factors into the final score. More Microsoft The study has its limitations. Microsoft's panel of 21 U.S. and U.K. doctors had a median of 12 years of experience but were not allowed to use search engines, language models or other sources of medical information when interacting with SDBench. These tools are common in physicians' practices, with about 1 in 5 using generative AI and about 7 in 10 using search engines on a regular basis, according to recent research—so the human participants may have achieved higher diagnostic accuracy if allowed to access their typical suite of online resources. Still, Microsoft's team says the research "highlight[s] how AI systems, when guided to think iteratively and act judiciously, can advance both diagnostic precision and cost-effectiveness in clinical care." MAI-DxO has not been deployed into production, but its initial performance offers a glimpse of high potential. The tool was developed by Microsoft AI's health effort, which launched quietly in late 2024 to create technology and conduct research that advances consumer health. A team of clinicians, designers, engineers and AI scientists have been collaborating under Suleyman, Microsoft AI CEO and co-founder of DeepMind (the AI company acquired by Google in 2014 for $400 million). Dr. Dominic King, Microsoft AI's heath vice president and a former lead at both Google DeepMind and Google Health, is also core to the work. "Two things that we're really proud of: creating a new benchmark for us to test the performance of AI against and showing that the orchestrator system that we created does stunningly well against that benchmark," King told Newsweek. "This is certainly the most exciting thing I've ever been part of." Each day, more than 50 million health-related searches are conducted across Microsoft's AI consumer products, including Copilot, Bing, Edge and MSN. Whether searching for a nearby urgent care center or attempting to make sense of a nagging headache, patients are increasingly turning to AI as a digital front door into the health system. There's a lot of pressure on tech companies like Microsoft to ensure patients find helpful answers. "We've got an AI called Copilot and people will come and talk about everything from their anxiety, to their child's headache, to much more serious conditions they're worried about," Suleyman said. "These are sustained conversational interactions. Copilot can do a better job for these folks if it has good expertise in diagnostics." Microsoft AI's research could also translate into gains for the health care industry, helping physicians reach an accurate diagnosis more quickly and with fewer expensive tests. Each year in the United States, 7.4 million people are misdiagnosed in emergency rooms, causing death or permanent disability in 1 in 350 patients, according to a 2023 study from the Agency for Healthcare Research and Quality. Plus, billions of dollars are spent on unnecessary tests—contributing to rising national health care costs and exacerbating terse relations between hospitals and insurance companies. Now, Microsoft is working closely with health systems (it declined to share which) and clinicians to set up more trials and attempt to replicate MAI-DxO's initial success. "This is a very promising sign of the potential," King said, "but we definitely see this as a multi-year journey that requires a lot of engagement across the health care system to get right."
